University of Washington Research May Lead to Metabolomic Dx for Certain Aggressive Cancers | GenomeWeb

In a study of metastatic neuroendocrine tumors in the lungs, thyroids, and prostates of transgenic mice, researchers at the Washington University School of Medicine in St. Louis have linked a high level of the neurotransmitter GABA with a poor prognosis for human patients with neuroendocrine cancers, a finding that may lead to diagnostics to guide treatment.

The study will appear in the July 12 issue of the Proceedings of the National Academy of Sciences, and it is currently available in the online version of the journal.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.